Research
Lactobacillus reuteri
131 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
Evaluating probiotic monotherapy in Helicobacter pylori infection: A meta-analysis of randomized controlled trials with trial sequential analysis.
This meta-analysis of 28 RCTs evaluated the effects of probiotics, particularly Lactobacillus reuteri, in reducing H. pylori colonization. Probiotic monotherapy significantly reduced colonization and improved gastrointestinal symptoms, though total eradication rates were low. The study suggests probiotics may be beneficial as supportive interventions.
The efficacy and acceptability of Lactobacillus reuteri for the treatment of depression: A systematic review and meta-analysis.
Systematic review and meta-analysis of 12 RCTs and 9 animal experiments on mixed probiotics containing Lactobacillus reuteri for depression treatment. Mixed probiotics were more effective than control in reducing depressive symptoms, with no significant difference in acceptability. L. reuteri alone did not improve depressive symptoms.
Clinical effects of Lactobacillus reuteri probiotic in chronic periodontitis - a systematic review.
This systematic review examines the effectiveness of Lactobacillus reuteri as an adjunct to scaling and root planing in the treatment of chronic periodontitis. Eleven studies with 369 subjects were included, showing mixed results on pocket depth and clinical attachment levels. The adjunctive use of Lactobacillus reuteri may provide some additional benefit in improving periodontal parameters.
Limosilactobacillus reuteri 6475 and Prevention of Early Postmenopausal Bone Loss: A Randomized Clinical Trial.
This randomized clinical trial evaluated the effect of daily supplementation with Limosilactobacillus reuteri on early postmenopausal bone loss in 239 women over 2 years. The study found no significant effect on bone loss or bone turnover, although an interaction between BMI and treatment effect was noted.
Limosilactobacillus reuteri DSM 17938 as a probiotic in preterm infants: An updated systematic review with meta-analysis and trial sequential analysis.
Updated systematic review and meta-analysis of Lactobacillus reuteri DSM 17938 in preterm infants. The analysis included 12 RCTs and 4 non-RCTs, showing that LR significantly reduced time to full feeds, necrotizing enterocolitis, and late-onset sepsis, but not mortality. The certainty of evidence was very low, and additional RCTs are needed.
A systematic review and meta-analysis: the therapeutic and preventive effect of Lactobacillus reuteri DSM 17,938 addition in children with diarrhea.
Systematic review and meta-analysis of 9 RCTs with 963 participants evaluating Lactobacillus reuteri for treating and preventing diarrhea in children. The addition of Lactobacillus reuteri significantly reduced the number of diarrhea cases and symptoms but had no significant effect on preventing various types of diarrhea.
Probiotics for infantile colic: Is there evidence beyond doubt? A meta-analysis and systematic review.
This meta-analysis and systematic review evaluated the effectiveness of probiotics, including Lactobacillus reuteri DSM 17938 and Bifidobacterium animalis lactis BB-12, in treating infantile colic. Probiotics resulted in an average reduction of 51 minutes of crying per day, with significant reductions observed in subgroups such as exclusively breastfed infants.
Efficacy of adjunctive measures in the non-surgical treatment of peri-implantitis: A systematic review.
Systematic review evaluating the efficacy of adjunctive measures in non-surgical peri-implantitis therapy. The review included studies on local/systemic antimicrobials and probiotics, specifically Lactobacillus reuteri strains. Systemic antimicrobials showed significant reductions in probing depth and bleeding on probing, while local antimicrobials led to modest improvements.
Evidence of Lactobacillus reuteri to reduce colic in breastfed babies: Systematic review and meta-analysis.
Systematic review and meta-analysis of 10 clinical trials investigating Lactobacillus reuteri supplementation in breastfed infants with colic. The administration of L. reuteri significantly reduced crying time and improved treatment effectiveness over four weeks, though confidence in the effect estimate is limited.
Tenth year reenrollment randomized trial investigating the effects of childhood probiotics and calcium supplementation on height and weight at adolescence.
This study investigated the long-term effects of childhood probiotics and calcium supplementation on growth in adolescence. Adolescents were re-enrolled 10 years after a 6-month supplementation with different combinations of calcium and probiotics. Changes in height-for-age and body mass index-for-age z-scores were assessed. No significant differences were found between groups, except a significant decrease in BMI z-score among female adolescents in the Lactobacillus casei group compared to regular calcium.
Effects of non-viable Lactobacillus reuteri combining with 14-day standard triple therapy on Helicobacter pylori eradication: A randomized double-blind placebo-controlled trial.
RCT of 200 H. pylori-positive adults comparing non-viable Lactobacillus reuteri DSM17648 with placebo alongside standard triple therapy. The study found no significant difference in H. pylori eradication rates, but the L. reuteri group showed improved gut microbial profile and reduced gastrointestinal symptoms.
Clinical effectiveness ofin the treatment of peri-implant diseases: a systematic review and meta-analysis.
Systematic review and meta-analysis evaluating the clinical effectiveness of Lactobacillus reuteri in the treatment of peri-implant diseases. The analysis included 6 articles, showing that LR may be clinically effective in reducing pocket depth in peri-implantitis and peri-implant mucositis, though not always achieving statistical significance.
The Effect of Probiotics on Symptoms, Gut Microbiota and Inflammatory Markers in Infantile Colic: A Systematic Review, Meta-Analysis and Meta-Regression of Randomized Controlled Trials
Systematic review and meta-analysis of 16 RCTs involving 1319 newborns with infantile colic, assessing the impact of probiotic therapy, predominantly Lactobacillus reuteri DSM17938. Probiotic intervention significantly reduced crying duration, but no causal relationship with microbiota modulation or immune system effects was confirmed.
Role of probiotics containing Lactobacillus reuteri in adjunct to scaling and root planing for management of patients with chronic periodontitis: a meta-analysis.
Meta-analysis of eleven randomized clinical trials evaluating the effect of Lactobacillus reuteri probiotics as an adjunct to scaling and root planing in chronic periodontitis. The study found significant short-term clinical and microbiological benefits, including reduction in probing pocket depth and gain in clinical attachment level.
A systematic review of prevention and treatment of infantile colic.
Systematic review evaluating interventions for infantile colic. Found moderately strong evidence that Lactobacillus reuteri DSM 17938 shortened crying duration in infants, while acupuncture showed no or minimal effect. More studies in diverse populations are needed.
Efficacy of Lactobacillus reuteri DSM 17938 for infantile colic: Systematic review with network meta-analysis.
Systematic review and network meta-analysis comparing the efficacy of Lactobacillus reuteri DSM 17938 with other interventions for infantile colic. L reuteri DSM 17938 and some dietetic approaches were found to be superior to other treatments in reducing the duration of crying in infants.
Systematic review with meta-analysis: Lactobacillus reuteri DSM 17938 for diarrhoeal diseases in children.
Systematic review and meta-analysis of eight RCTs (n = 1229) evaluating Lactobacillus reuteri DSM 17938 for diarrhoeal diseases in children. L. reuteri reduced the duration of diarrhoea and increased cure rates in treatment trials, but showed no significant effect in preventive trials for nosocomial or antibiotic-associated diarrhoea.
Lactobacillus reuteri DSM 17938 as a Probiotic for Preterm Neonates: A Strain-Specific Systematic Review.
Systematic review of RCTs and non-RCTs assessing Lactobacillus reuteri DSM 17938 in preterm neonates. Meta-analysis showed reduced time to full feeds, duration of hospitalization, and late-onset sepsis in the L reuteri group. Mortality and NEC were reduced but not statistically significant. No adverse effects were reported.
The Efficacy and Safety of the Probiotic Bacterium Lactobacillus reuteri DSM 17938 for Infantile Colic: A Meta-Analysis of Randomized Controlled Trials.
Meta-analysis of six randomized controlled trials involving 423 infants with colic, comparing Lactobacillus reuteri DSM 17938 to placebo. L. reuteri increased colic treatment effectiveness and decreased crying time at two and three weeks without causing adverse events. The study highlights the need for higher quality trials due to heterogeneity.
Probiotics to prevent or treat excessive infant crying: systematic review and meta-analysis.
Systematic review and meta-analysis of 12 trials involving 1825 infants to assess the effectiveness of probiotics in preventing or managing excessive infant crying (colic). Results were mixed, with some trials suggesting Lactobacillus reuteri reduced crying in breastfed infants, but overall evidence was insufficient to support probiotic use for colic management or prevention.
Probiotics for infantile colic: a systematic review.
Systematic review and meta-analysis of randomized controlled trials evaluating the efficacy of Lactobacillus reuteri supplementation in reducing crying time in breastfed infants with colic. Probiotic supplementation significantly shortened crying times and increased treatment success compared to simethicone or placebo.
Impact of Subgingival Lactobacillus reuteri Probiotic Therapy on Clinical Outcomes and Porphyromonas gingivalis Quantification in Peri-Implant Disease: A Prospective RT-PCR-Based Clinical Study.
Prospective clinical study evaluating the effects of subgingival Lactobacillus reuteri probiotic therapy as an adjunct to mechanical debridement in peri-implantitis management. The probiotic group showed significantly greater improvements in clinical parameters and reductions in Porphyromonas gingivalis levels compared to mechanical debridement alone.
Interpheron type II signature in mucosal swabs of patient with infantile colic treated with Limosilactobacillus reuteri (L. reuteri) LMG P-27481.
RCT investigating the effect of L. reuteri LMG P-27481 on immune gene expression in the oral mucosa of colicky infants. L. reuteri administration significantly upregulated immune-related genes, suggesting enhanced local immune surveillance and a shift towards immune tolerance, indicating its role in promoting immune homeostasis.
Lactobacillus reuteri protectis DSM 17938 at high doses versus placebo in children with acute gastroenteritis in a Pediatric Emergency Department.
RCT conducted in a pediatric emergency department to assess the efficacy of Lactobacillus reuteri DSM 17938 adjunct to oral rehydration therapy in children with acute gastroenteritis. The probiotic group showed reduced duration and frequency of diarrhea compared to placebo, indicating effectiveness in managing acute gastroenteritis.
Clinical Effects of Lactobacillus reuteri on Gingival Inflammation and Alveolar Bone Loss in Periodontitis.
This randomized, double-blind, placebo-controlled trial evaluated the efficacy of Lactobacillus reuteri in reducing gingival inflammation and alveolar bone loss in periodontitis. The L. reuteri group showed significant reductions in inflammatory markers and improvements in probing depth, clinical attachment level, and radiographic bone loss compared to placebo.
The impact of probiotics on pulmonary, gastrointestinal, and growth outcomes in pediatric cystic fibrosis: a randomized controlled trial.
This double-blind randomized controlled trial examined the effects of Lactobacillus reuteri on pulmonary, gastrointestinal, and growth outcomes in 110 pediatric cystic fibrosis patients. While probiotics improved quality of life, no significant effects were observed on pulmonary, gastrointestinal, or growth-related outcomes.
The efficacy of lactobacillus reuteri in conjunction with racecadotril in managing pediatric rotavirus enteritis and its impact on intestinal mucosa and immune function.
RCT evaluating the combination of Lactobacillus reuteri and racecadotril in 85 children with pediatric rotavirus enteritis. The combination treatment improved RV conversion rates, mucosal barrier function, immune response, and intestinal microbiota compared to racecadotril alone.
Probiotics Enhance Bone Density and Reduce Inflammation Postalveolar Surgery.
Open-label trial of 80 patients undergoing alveolar surgery, comparing Lactobacillus reuteri probiotics to standard care. The probiotic group showed a 3.8% higher bone density and reduced proinflammatory cytokines, suggesting enhanced alveolar bone stability and reduced inflammation.
Add-on probiotics for inflammatory depression - A double-blind randomized placebo-controlled trial.
This double-blind RCT tested the adjunctive antidepressant efficacy of a Lactobacillus reuteri probiotic in depressed patients with systemic low-grade inflammation. No significant effects were found on primary or secondary outcomes compared to placebo. However, a greater increase in fecal formic acid was associated with a decrease in depression scores in the probiotics group.
Effect of Nitazoxanide and Probiotic Treatment on Bangladeshi Children with Cryptosporidiosis.
Pilot RCT in Bangladeshi children with cryptosporidiosis comparing NTZ and Lactobacillus reuteri treatment to NTZ with placebo and standard care. No difference in infection duration or growth improvement was observed across treatment groups.
Treatment of Peri-implant Mucositis: An AAP/AO Systematic Review and Meta-analysis.
Systematic review and meta-analysis assessing adjunctive treatment modalities in combination with peri-implant debridement for peri-implant mucositis. The use of certain probiotics, such as Lactobacillus reuteri strains, may modestly reduce bleeding on probing in the short term, but complete disease resolution was not consistently achieved.
Effect of Lactobacillus reuteri NCIMB 30351 drops on symptoms of infantile functional gastrointestinal disorders and gut microbiota in early infants: Results from a randomized, placebo-controlled clinical trial.
RCT of 90 infants aged 1 to 4 months evaluating the effects of Lactobacillus reuteri NCIMB 30351 drops on symptoms of infantile colic, constipation, diarrhea, and gastroesophageal reflux. The probiotic significantly reduced colic, crying duration, regurgitations, and improved gut microbiota composition.
Efficacy and Safety of Postbiotic Contained Inactivated Lactobacillus reuteri ( Limosilactobacillus reuteri ) DSM 17648 as Adjuvant Therapy in the Eradication of Helicobacter pylori in Adults With Functional Dyspepsia: A Randomized Double-Blind Placebo-Controlled Trial.
This randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of postbiotic containing inactivated Limosilactobacillus reuteri DSM 17648 as an adjuvant therapy for Helicobacter pylori eradication in patients with functional dyspepsia. The postbiotic group showed a higher eradication efficiency (96.7%) compared to the placebo group (86.0%), with fewer digestive adverse effects.
Probiotic containing Lactobacillus reuteri DSM 17648 as an adjunct treatment for Helicobacter pylori infection: A randomized, double-blind, placebo-controlled trial.
This randomized, double-blind, placebo-controlled trial investigated the efficacy of Lactobacillus reuteri DSM 17648 as an adjunct treatment for Helicobacter pylori infection. The probiotic group showed a higher eradication rate and significant reductions in gastrointestinal symptoms and adverse treatment effects compared to the placebo group.
Effect of probiotics on mother-to-neonate vertical transmission of group B streptococci: A prospective open-label randomized study.
Prospective open-label randomized study of 67 mother-infant pairs assessing the effect of Lactobacillus reuteri on mother-to-child transmission of Group B Streptococci. The probiotic group showed a lower positivity rate of GBS in newborns at 1 month of age compared to the control group, though the difference was not statistically significant.
Effect of lactobacillus reuteri-derived probiotic nano-formulation on recurrent aphthous stomatitis: a double-blinded randomized clinical trial.
Double-blinded randomized clinical trial assessing the effects of a topical probiotic nano-formulation derived from Lactobacillus reuteri on recurrent aphthous stomatitis. The probiotic group showed significantly greater reductions in lesion size and pain severity compared to the control group using a standard analgesic oral rinse.
A placebo-controlled randomized clinical trial of antibiotics versus probiotics as an adjuvant to nonsurgical periodontal treatment among smokers with Stage III, Grade C generalized periodontitis.
RCT comparing the effects of antibiotics versus Lactobacillus reuteri probiotics as an adjuvant to nonsurgical periodontal treatment in 60 smokers with Stage III, Grade C generalized periodontitis. Both groups showed significant clinical improvement in periodontal parameters at 3-month follow-up, but no significant differences between groups.
Precision microbial intervention improves social behavior but not autism severity: A pilot double-blind randomized placebo-controlled trial.
Double-blind, randomized, placebo-controlled trial testing L. reuteri (strains ATCC-PTA-6475 and DSM-17938) in children with ASD. The treatment improved social functioning but did not alter overall autism severity, restricted/repetitive behaviors, microbiome composition, or immune profile.
Randomized, double-blind, placebo-controlled clinical trial on the usefulness of probiotic Lactobacillus reuteri in bismuth-containing quadruple eradication therapy for infection with Helicobacter pylori.
RCT comparing gastrointestinal symptom reduction in patients on bismuth-containing quadruple eradication therapy supplemented with Lactobacillus reuteri or placebo. The probiotic group showed a significant reduction in abdominal pain and distension compared to the control group.
Chronic consumption of probiotics, oats, and apples has differential effects on postprandial bile acid profile and cardiometabolic disease risk markers compared with an isocaloric control (cornflakes): a randomized trial.
RCT with 61 volunteers comparing the effects of probiotics, oats, and apples on postprandial bile acids and cardiometabolic health markers. Probiotics increased postprandial unconjugated and hydrophobic bile acid responses, while oats and apples decreased postprandial serum insulin and C-peptide responses.
Investigation and comparison of the effects of two probiotic bacteria, and in reducing mutans streptococci levels in the saliva of children.
RCT with 60 children aged 6-14 years evaluating the effect of Lactobacillus reuteri and Bifidobacterium bifidum on mutans streptococci levels in saliva. Lactobacillus reuteri significantly reduced mutans streptococci levels, with effects lasting up to 21 days. Mixed cultures were not effective.
The Effects of Limosilactobacillus reuteri LR-99 Supplementation on Body Mass Index, Social Communication, Fine Motor Function, and Gut Microbiome Composition in Individuals with Prader-Willi Syndrome: a Randomized Double-Blinded Placebo-Controlled Trial.
A 12-week randomized, double-blind, placebo-controlled trial in 71 individuals with Prader-Willi syndrome evaluated the effects of Lact. reuteri LR-99 supplementation. The probiotic group showed significant reductions in BMI, improvements in social communication, fine motor function, and altered gut microbiota favoring weight loss and improved gut health.
The efficacy of the prenatal administration of Lactobacillus reuteri LR92 DSM 26866 on the prevention of infantile colic: a randomized control trial.
This double-blinded, placebo-controlled, randomized trial studied the prenatal administration of Lactobacillus reuteri LR92 DSM 26866 in 145 pregnant women to prevent infantile colic. Mothers who received the probiotic were less likely to have infants with colic, and the severity of colic was significantly lower in the intervention group.
Effectiveness of scaling and root planing with and without adjunct probiotic therapy in the treatment of chronic periodontitis among shamma users and non-users: A randomized controlled trial.
RCT comparing the effectiveness of scaling and root planing (SRP) with and without adjunct probiotic therapy (Lactobacillus reuteri) in treating chronic periodontitis among shamma users and non-users. Among non-users, SRP with adjunct probiotic therapy was more effective in reducing plaque index, bleeding on probing, and probing depth at 3-month follow-up. No significant differences were observed among shamma users.
Consumption of Lactobacillus reuteri-containing lozenges improves periodontal health in navy sailors at sea: A randomized controlled trial.
RCT involving 72 navy sailors to evaluate the effect of Lactobacillus reuteri-containing lozenges on periodontal health. The test group showed significant improvements in periodontal health parameters compared to the placebo group over 42 days.
Lactobacillus reuteri DSM 17938 and Magnesium Oxide in Children with Functional Chronic Constipation: A Double-Blind and Randomized Clinical Trial.
A double-blind, randomized clinical trial evaluated the efficacy of Lactobacillus reuteri DSM 17938 and magnesium oxide in relieving chronic functional constipation in children. Both substances improved defecation frequency, but magnesium oxide also altered the gut microbiome, unlike the probiotic.
Lactobacillus reuteri DSM 17938 in the prevention of antibiotic-associated diarrhoea in children: a randomized clinical trial.
RCT assessing Lactobacillus reuteri DSM 17938 for preventing diarrhoea and antibiotic-associated diarrhoea (AAD) in 247 hospitalized children receiving antibiotics. The occurrences of diarrhoea and AAD were similar in both the L. reuteri and placebo groups, indicating no significant effect.
Probiotic administration among free-living older adults: a double blinded, randomized, placebo-controlled clinical trial.
Double-blinded, randomized, placebo-controlled clinical trial evaluating the effect of Lactobacillus reuteri on digestive health and wellbeing in older adults. No significant effects were observed on primary or secondary outcomes, though a modest decrease in stress and anxiety was noted in the probiotic arm at certain time points.
Probiotics for the Treatment of Infantile Colic: A Systematic Review.
Systematic review of RCTs evaluating probiotic supplementation with Lactobacillus reuteri in infants with colic. Infants receiving probiotics had a 2.3-fold greater chance of reducing crying/fussing time by 50% or more compared to controls, with no adverse events reported.
Effect of Probiotic Bacteria on Oral Candida in Frail Elderly.
Double-blind randomized placebo-controlled trial investigating the effect of daily probiotic lactobacilli intake on oral Candida prevalence in frail elderly patients. The probiotic group showed a significant reduction in high Candida counts compared to placebo, with no significant differences in dental plaque or gingival inflammation.
Diarrhea in preschool children and Lactobacillus reuteri: a randomized controlled trial.
RCT of 336 healthy children in Mexico evaluating daily administration of Lactobacillus reuteri DSM 17938. The probiotic significantly reduced the frequency and duration of diarrhea and respiratory tract infections, as well as doctor visits, antibiotic use, and absenteeism, with cost savings.
Comparison of Lactobacillus reuteri and nystatin prophylaxis on Candida colonization and infection in very low birth weight infants.
RCT comparing the efficacy of Lactobacillus reuteri versus nystatin in preventing fungal colonization and invasive candidiasis in very low birth weight infants. L. reuteri was as effective as nystatin in preventing colonization and more effective in reducing proven sepsis and feeding intolerance.
The efficacy of Lactobacillus reuteri DSM 17938 in infants and children: a review of the current evidence.
Systematic review evaluating the effectiveness of Lactobacillus reuteri DSM 17938 in infants and children. L. reuteri may help manage acute gastroenteritis and reduce diarrhea incidence in day care children, but not nosocomial diarrhea. It may reduce crying time in breast-fed infants with colic, but not in formula-fed infants. Preliminary evidence suggests potential benefits for functional gastrointestinal disorders, though more research is needed.
Probiotics Lactobacillus reuteri DSM 17938 and Lactobacillus casei CRL 431 modestly increase growth, but not iron and zinc status, among Indonesian children aged 1-6 years.
A 6-month randomized trial in Jakarta assessed the effects of probiotics Lactobacillus reuteri DSM 17938 and Lactobacillus casei CRL 431 on growth and iron and zinc status in Indonesian children. L. reuteri modestly improved growth metrics such as weight gain and height velocity, while L. casei improved weight velocity. No significant effects on iron and zinc status were observed.
Randomized trial of probiotics and calcium on diarrhea and respiratory tract infections in Indonesian children.
RCT in 494 Indonesian children aged 1 to 6 years tested effects of calcium and probiotics on diarrhea and ARTIs. L reuteri significantly reduced diarrhea incidence, especially in children with lower nutritional status, but none of the interventions affected ARTIs.
[Which treatments for infantile colics?].
Systematic review assessing treatments for infantile colics. The review found effectiveness for probiotics (Lactobacillus reuteri) and herbal mixtures containing fennel extracts. Allopathic drugs like simethicone and lactase were not effective, and some could cause adverse reactions.
Efficacy of Lactobacillus reuteri DSM 17938 in Thai children with acute gastroenteritis and normal or mild dehydration in an outpatient setting: a randomized controlled trial.
RCT in Thai children with acute diarrhoea comparing Lactobacillus reuteri DSM 17938 to placebo. The L. reuteri group had a significantly shorter median time for diarrhoea resolution and higher recovery rates within 48 and 72 hours.
Resilience of the Gut Microbiome to Short Proton Pump Inhibitor Therapy With or Without High-Dosage L. reuteri in H. pylori-Infected Adults.
Double-blind, randomized trial of pantoprazole plus Lactobacillus reuteri (high dose) or placebo in H. pylori-positive adults. L. reuteri was detected only at 1 month post-treatment and failed to alter gut microbiota diversity metrics. The gut microbiota returned to baseline shortly after therapy.
The effect of Lactobacillus reuteri on pulmonary function test and growth of cystic fibrosis patients.
RCT investigating the effect of Lactobacillus reuteri supplementation on pulmonary function, respiratory symptoms, and growth in 40 children with cystic fibrosis. Significant improvement in BMI z-score was observed in the probiotic group, and a reduction in Pseudomonas aeruginosa growth in sputum cultures was noted.
Effect of adjuvant probiotic therapy (Lactobacillus reuteri) in the treatment of periodontitis associated with diabetes mellitus: clinical, controlled, and randomized study.
RCT evaluating Lactobacillus reuteri probiotics as adjunctive therapy in periodontitis treatment for patients with type 2 diabetes mellitus. The probiotics showed no additional effects on periodontal parameters compared to placebo, but had a positive effect on lipoprotein subfractions.
Effect of systemic antibiotic and probiotic therapies as adjuvant treatments of subgingival instrumentation for periodontitis: a randomized controlled clinical study.
RCT assessing the efficacy of antibiotic and probiotic (Lactobacillus reuteri) therapies as adjuncts to periodontal treatment in 45 patients with periodontitis. Both therapies reduced bleeding on probing and inflammation, with the probiotic group showing better results for plaque index and gingival recession compared to the antibiotic group at 90 days. No additional benefit was observed for subgingival instrumentation after three months.
One-year supplementation with Lactobacillus reuteri ATCC PTA 6475 counteracts a degradation of gut microbiota in older women with low bone mineral density.
RCT of Lactobacillus reuteri ATCC PTA 6475 supplementation in older women with low bone mineral density. The study found that the probiotic reduced bone loss, improved gut microbiota gene richness, and reduced inflammatory state in good responders after one year.
Urinary metabolome of infants with colic treated with Lactobacillus reuteri DSM 17938: a pilot randomized trial.
This pilot randomized, blinded, placebo-controlled trial examined the urinary metabolomic fingerprint of colicky breastfed infants treated with Lactobacillus reuteri DSM 17938. The study found that metabolites in the probiotic-treated group were more abundant after the study period compared to the placebo group, suggesting an effect on the urinary metabolome.
"The role of L. reuteri DSM17938 in nutritional recovery and treatment of constipation in children and adolescents with anorexia nervosa - a randomized, double blind, placebo controlled study".
RCT of 31 female pediatric patients with anorexia nervosa and constipation, comparing L. reuteri DSM17938 to placebo over 3 months. The L. reuteri group showed increased stool frequency and improved nutritional recovery, but no significant effect on constipation relief at 3 months. Bone mineral density normalization was not significantly different between groups.
Oral Microbial Shift Following 1-Month Supplementation of Probiotic Chewable Tablets Containing Lactobacillus reuteri UBLRu-87 as an Adjunct to Phase 1 Periodontal Therapy in Chronic Periodontitis Patients: A Randomized Controlled Clinical Trial
This randomized controlled clinical trial evaluated the effects of probiotic chewable tablets containing Lactobacillus reuteri UBLRu-87 as an adjunct to initial periodontal therapy in chronic periodontitis patients. The study found significant improvements in clinical and microbiological parameters in the group receiving the probiotic compared to the control group.
Post hoc analysis of fecal samples from responders and non-responders to Lactobacillus reuteri DSM 17938 intervention.
Post hoc analysis of fecal samples from 44 children (17 responders and 27 non-responders) to Lactobacillus reuteri DSM 17938 intervention for acute gastroenteritis. No differences in clinical characteristics and gut colonization were found between groups, but responders had lower levels of certain metabolites before intervention and lower fecal calprotectin levels after intervention.
A Randomized Controlled Open Label Crossover Trial to Study Vaginal Colonization of Orally Administered Lactobacillus Reuteri RC-14 and Rhamnosus GR-1 in Pregnant Women at High Risk for Preterm Labor.
RCT evaluating vaginal colonization of orally administered Lactobacillus reuteri RC-14 and Rhamnosus GR-1 in 40 pregnant women at high risk for preterm birth. Vaginal colonization of lactobacilli was low, with GR-1 detected in a small percentage of women and RC-14 not detected.
Pre- and postnatal Lactobacillus reuteri treatment alters DNA methylation of infant T helper cells.
This study assessed the effects of pre- and postnatal Lactobacillus reuteri supplementation on DNA methylation in relation to immune maturation and allergy development. The greatest genome-wide differential DNA methylation was observed at birth, with hypomethylation indicating transcriptional accessibility in the probiotic group. Maternal L. reuteri supplementation during pregnancy altered DNA methylation patterns in CD4+ T cells towards enhanced immune activation at birth.
Effects of Lactobacillus reuteri DSM 17938 in preterm infants: a double-blinded randomized controlled study.
Double-blinded RCT of 114 formula-fed preterm infants evaluating the effects of Lactobacillus reuteri DSM 17938 on early feeding tolerance, growth, and infection prevention. The intervention group showed improved feeding tolerance, growth, increased defecation frequency, and shorter hospital stays, with no significant differences in infection rates.
Twice-a-day PPI, tetracycline, metronidazole quadruple therapy with Pylera® or Lactobacillus reuteri for treatment naïve or for retreatment of Helicobacter pylori. Two randomized pilot studies.
Two open-label randomized pilot studies investigated the efficacy of b.i.d. quadruple therapy containing Pylera or Lactobacillus reuteri for Helicobacter pylori infection. The study enrolled 99 subjects, with 92 completing it. The Pylera group showed a higher cure rate compared to the Gastrus group, but both regimens were effective with excellent compliance and mild side effects.
Supplementation with Lactobacillus reuteri ATCC PTA 4659 in patients affected by acute uncomplicated diverticulitis: a randomized double-blind placebo controlled trial.
A double-blind, placebo-controlled RCT tested the efficacy of Lactobacillus reuteri 4659 in treating acute uncomplicated diverticulitis in 88 patients. Supplementation with L. reuteri significantly reduced abdominal pain and inflammatory markers compared to placebo, and resulted in a shorter hospitalization period.
Safety of Lactobacillus Reuteri DSM 17938 in Healthy Children 2-5 Years of Age.
Phase-one placebo-controlled study of Lactobacillus reuteri DSM 17938 in 60 children aged 2-5 years in Peru. No differences in objective data on adverse events were noted, though some differences based on subjective parental reports for fever and diarrhea were observed.
A double-blind, paralleled-arm, placebo-controlled and randomized clinical trial of the effectiveness of probiotics as an adjunct in periodontal care.
A double-blind, placebo-controlled RCT evaluated the effectiveness of Lactobacillus reuteri as an adjunct to non-surgical periodontal therapy (NSPT) in 59 participants. The study found significant intra-group improvements in clinical attachment levels and probing pocket depths, but no significant inter-group differences, indicating no additional clinical effectiveness of probiotics over NSPT alone.
Probiotics promoted head growth in extremely low birthweight infants in a double-blind placebo-controlled trial.
A double-blind, placebo-controlled trial with 134 extremely low birthweight infants evaluated the effects of Lactobacillus reuteri supplementation on feeding tolerance and growth rates. While feeding tolerance was similar between groups, the L. reuteri group showed a less significant decrease in head circumference z-score compared to placebo, indicating better head growth.
The effectiveness of Lactobacillus reuteri DSM 17938 as an adjunct to macrogol in the treatment of functional constipation in children. A randomized, double-blind, placebo-controlled, multicentre trial.
This randomized, double-blind, placebo-controlled, multicentre trial assessed the effectiveness of Lactobacillus reuteri DSM 17938 as an adjunct to macrogol in treating functional constipation in children. The study found no statistically significant difference in bowel movements or symptoms between the probiotic and placebo groups after 8 weeks.
Lactobacillus reuteri reduces bone loss in older women with low bone mineral density: a randomized, placebo-controlled, double-blind, clinical trial.
RCT investigating the effect of Lactobacillus reuteri 6475 on bone loss in older women with low bone mineral density. L. reuteri 6475 reduced loss of total volumetric bone mineral density compared to placebo, suggesting potential benefits for bone health.
The beneficial effects of Lactobacillus reuteri ADR-1 or ADR-3 consumption on type 2 diabetes mellitus: a randomized, double-blinded, placebo-controlled trial.
A randomized, double-blinded, placebo-controlled trial with 68 T2DM patients examined the effects of Lactobacillus reuteri strains ADR-1 and ADR-3. Significant reductions in HbA1c and serum cholesterol were observed in the ADR-1 group, while the ADR-3 group showed decreased blood pressure. Changes in intestinal flora were associated with probiotic intake.
Evaluation of the effect of Lactobacillus reuteri V3401 on biomarkers of inflammation, cardiovascular risk and liver steatosis in obese adults with metabolic syndrome: a randomized clinical trial (PROSIR).
This randomized, double-blind, crossover, placebo-controlled trial evaluates the effects of Lactobacillus reuteri V3401 on intestinal microbiota composition, insulin resistance markers, and biomarkers of inflammation, cardiovascular risk, and hepatic steatosis in 60 obese adults with metabolic syndrome. The primary outcome is the change in plasma lipopolysaccharide levels after 12 weeks.
Effects of long-term administration of Lactobacillus reuteri DSM-17938 on circulating levels of 5-HT and BDNF in adults with functional constipation.
RCT investigating the effects of long-term administration of Lactobacillus reuteri DSM 17938 on serum levels of serotonin (5-HT) and brain-derived neurotrophic factor (BDNF) in 56 adults with functional constipation. The study found that probiotic administration significantly lowered 5-HT and BDNF levels, suggesting potential improvement in functional constipation.
Efficacy of an Oral Rehydration Solution Enriched with Lactobacillus reuteri DSM 17938 and Zinc in the Management of Acute Diarrhoea in Infants: A Randomized, Double-Blind, Placebo-Controlled Trial
This randomized, double-blind, placebo-controlled trial assessed the efficacy of an oral rehydration solution enriched with Lactobacillus reuteri DSM 17938 and zinc in 51 infants with acute diarrhoea. Both the enriched and standard ORS reduced diarrhoea severity, with a trend towards better outcomes in the enriched group, though not statistically significant. No adverse effects were recorded.
Oral probiotics in the management of gingivitis in diabetic patients: a double blinded randomized controlled study.
RCT evaluating the effect of Lactobacillus Reuteri probiotics on gingivitis in 80 diabetic patients. The test group receiving probiotics showed significant reductions in plaque and bleeding on probing compared to baseline and control.
Rapid enteric testing to permit targeted antimicrobial therapy, with and without Lactobacillus reuteri probiotics, for paediatric acute diarrhoeal disease in Botswana: A pilot, randomized, factorial, controlled trial.
Pilot, randomized, factorial, controlled trial in Botswana assessing the feasibility of rapid enteric testing and Lactobacillus reuteri DSM 17938 probiotics for acute diarrhoeal disease in children. The combination of rapid test-and-treat strategy plus L. reuteri was associated with an increase in age-standardized height and significantly lower odds of recurrent diarrhoea at 60 days.
Lactobacillus reuteri DSM 17938 and a placebo both significantly reduced symptoms in children with functional abdominal pain.
RCT of 54 children with functional abdominal pain comparing Lactobacillus reuteri DSM 17938 to placebo for four weeks. Both groups showed significant reductions in pain frequency and intensity, but only L. reuteri improved normal activities without side effects.
Effectiveness of Lactobacillus reuteri DSM 17938 for the Prevention of Nosocomial Diarrhea in Children: A Randomized, Double-blind, Placebo-controlled Trial.
RCT assessing the effectiveness of Lactobacillus reuteri DSM 17938 in preventing nosocomial diarrhea in 184 hospitalized children. No significant difference was found between the L. reuteri and placebo groups in preventing diarrhea or in secondary outcomes.
Safety and acceptability of Lactobacillus reuteri DSM 17938 and Bifidobacterium longum subspecies infantis 35624 in Bangladeshi infants: a phase I randomized clinical trial.
Phase I randomized clinical trial investigating the safety and acceptability of Lactobacillus reuteri DSM 17938 and Bifidobacterium longum subspecies infantis 35624 in Bangladeshi infants. The study found that these probiotics were safe and well-accepted, with similar illness and breastfeeding rates across all intervention and control arms.
Lactobacillus reuteri DSM 17938 for the Management of Functional Abdominal Pain in Childhood: A Randomized, Double-Blind, Placebo-Controlled Trial.
RCT of 101 children with functional abdominal pain comparing Lactobacillus reuteri DSM 17938 to placebo for 4 weeks. L reuteri significantly reduced the frequency and intensity of abdominal pain compared to placebo.
Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis.
RCT involving 50 NASH patients to assess synbiotic supplementation effects on metabolic parameters, hepatic steatosis, and gut health. Synbiotic group showed reduced steatosis, weight loss, and decreased BMI and waist circumference, but no improvement in intestinal permeability or LPS levels.
Infant Colic-What works: A Systematic Review of Interventions for Breast-fed Infants.
Systematic review and meta-analysis of interventions for colic in breast-fed infants. Probiotics, particularly Lactobacillus reuteri, and preparations containing fennel oil appear effective in reducing colic symptoms. Evidence for other interventions like maternal dietary changes and simethicone is weak.
Microbial lysate upregulates host oxytocin.
The study demonstrates that dietary supplementation with a sterile lysate of Lactobacillus reuteri is sufficient to boost systemic oxytocin levels and improve wound repair capacity in humans. In mouse models, it was shown that this supplementation increased oxytocin-producing cells in the hypothalamus, lowered blood levels of stress hormone corticosterone, and accelerated epidermal closure.
Preventive effects of oral probiotic on infantile colic: a prospective, randomised, blinded, controlled trial using Lactobacillus reuteri DSM 17938.
RCT of 113 infants comparing Lactobacillus reuteri DSM 17938 with vitamin D3 to vitamin D3 alone for infantile colic. L. reuteri supplementation reduced the use of pain relieving agents, the switch to formula feeding, and the number of pediatric consultations for colic.
Treating infant colic with the probiotic Lactobacillus reuteri: double blind, placebo controlled randomised trial.
Double blind, placebo controlled RCT of 167 infants with colic, testing the effect of Lactobacillus reuteri DSM 17938 on crying and fussing. The probiotic group cried or fussed 49 minutes more than the placebo group at 1 month, with no benefit observed on secondary outcomes.
Lactobacillus reuteri DSM 17938 effectively reduces the duration of acute diarrhoea in hospitalised children.
A multicentre, randomised, single-blind clinical trial in hospitalised children with acute gastroenteritis evaluated the use of Lactobacillus reuteri DSM 17938. The probiotic reduced the duration of diarrhoea and hospital stays, with more diarrhoea-free children in the treatment group compared to controls. No adverse effects were reported.
Lactobacillus reuteri strain combination in Helicobacter pylori infection: a randomized, double-blind, placebo-controlled study.
RCT of 100 H. pylori-positive patients comparing Lactobacillus reuteri combination to placebo. L. reuteri combination decreased C-UBT levels, reduced antibiotic-associated side effects, and decreased serum G17 levels. It also increased the H. pylori eradication rate by 9.1%, though not significantly.
Lactobacillus reuteri ATCC55730 in cystic fibrosis.
RCT evaluating the effect of Lactobacillus reuteri on respiratory exacerbations and infections in cystic fibrosis patients. The LR group showed significant reductions in pulmonary exacerbations and upper respiratory tract infections compared to placebo, though no significant differences were found in hospitalizations or gastrointestinal infections.
Probiotics for infantile colic: a randomized, double-blind, placebo-controlled trial investigating Lactobacillus reuteri DSM 17938.
RCT investigating the effectiveness of Lactobacillus reuteri DSM 17938 for treating infantile colic in breastfed Canadian infants. The probiotic group showed significantly shorter crying and fussing times compared to placebo, with a higher proportion of infants achieving a ≥50% reduction in crying time.
Oral administration of Lactobacillus reuteri during the first year of life reduces caries prevalence in the primary dentition at 9 years of age.
Single-blind, placebo-controlled multicenter trial involving 113 children to evaluate the effect of daily oral supplementation with Lactobacillus reuteri on oral health at age 9. The probiotic group had a higher percentage of caries-free children and lower prevalence of approximal caries lesions and gingivitis compared to the placebo group.
Lactobacillus reuteri influences regrowth of mutans streptococci after full-mouth disinfection: a double-blind, randomised controlled trial.
This double-blind, randomised controlled trial assessed the effect of Lactobacillus reuteri on the regrowth of mutans streptococci (MS) after full-mouth disinfection with chlorhexidine in 62 healthy subjects. The test group used probiotic lozenges containing L. reuteri, while the placebo group used lozenges without lactobacilli. The presence of L. reuteri was associated with slower regrowth of MS.
Probiotics to improve outcomes of colic in the community: protocol for the Baby Biotics randomised controlled trial.
The Baby Biotics trial is a double-blind, placebo-controlled randomized trial in Melbourne, Australia, aiming to determine whether the probiotic Lactobacillus reuteri DSM 17938 is effective in reducing crying in infants less than three months old with colic. The trial involves 160 breast and formula-fed infants, with primary and secondary outcomes including infant crying/fussing time, sleep duration, maternal mental health scores, and infant faecal microbiota diversity.
Evaluation of clinical safety and tolerance of a Lactobacillus reuteri NCIMB 30242 supplement capsule: a randomized control trial.
RCT evaluating the clinical safety and tolerance of Lactobacillus reuteri NCIMB 30242 supplement capsules in 131 subjects over 9 weeks. No clinically significant differences in safety parameters or adverse events were found between the probiotic and placebo groups.
Lack of an effect of Lactobacillus reuteri DSM 17938 in preventing nosocomial diarrhea in children: a randomized, double-blind, placebo-controlled trial.
RCT of 106 hospitalized children evaluating Lactobacillus reuteri DSM 17938 for preventing nosocomial diarrhea. The probiotic showed no significant effect on the risk of developing nosocomial diarrhea or rotavirus infection compared to placebo.